Medicare Didn’t Investigate Suspicious Reports Of Hospital Infections

http://www.npr.org/sections/health-shots/2017/05/09/527432852/medicare-didnt-investigate-suspicious-reports-of-hospital-infections

Almost 100 hospitals reported suspicious data on dangerous infections to Centers for Medicare & Medicaid Services officials, but the agency did not follow up or examine any of the cases in depth, according to a report by the Health and Human Services inspector general’s office.

Most hospitals report how many infections strike patients during treatment, meaning the infections are likely contracted inside the facility. Each year, Medicare is supposed to review up to 200 cases in which hospitals report suspicious infection-tracking results.

The IG said Medicare should have done an in-depth review of 96 hospitals that submitted “aberrant data patterns” in 2013 and 2014. Such patterns could include a rapid change in results, improbably low infection rates or assertions that infections nearly always struck before patients arrived at the hospital.

The IG’s report, released Thursday, was designed to address concerns over whether hospitals are “gaming” a system in which it falls to the hospitals to report patient infection rates and, in turn, the facilities can see a bonus or a penalty worth millions of dollars.

The bonuses and penalties are part of Medicare’s Hospital Inpatient Quality Reporting program, which is meant to reward hospitals for low infection rates and give consumers access to the information at the agency’s Hospital Compare website.

Altarum Institute Urges CMS to Adopt Physician-Focused Payment Models

http://altarum.org/about/news-and-events/altarum-institute-urges-cms-to-adopt-physician-focused-payment-models

Image result for Physician-Focused Payment Models

Altarum Institute joins the debate over whether the Centers for Medicare & Medicaid Services (CMS) should delay expansion of its controversial bundled payment programs, specifically the Comprehensive Care for Joint Replacement (CJR) pilot and the cardiac care bundled payment initiative (also known as the Episode Payment Models, or EPM).

In a column published today in Health Affairs, Altarum Vice President and Director of the Center for Payment Innovation, François de Brantes, argues that CMS should delay and ultimately replace its Bundled Payment for Care Improvement (BPCI) program with a physician-focused model.

De Brantes writes that the BPCI program has five flaws that physician-focused models do not have, and those flaws are serious enough to compromise the successful long-term adoption of bundled payment models, which are critical to reducing health care costs and improving outcomes.

“I applaud CMS’s effort to launch bundled payment models, but the current models they have introduced—the CJR pilot and EPM—are inherently flawed, and unlikely to be successful,” says de Brantes.

The five flaws are outlined in detail in the Health Affairs article and in a public comment letter to CMS from Altarum President and CEO Lincoln Smith. They are summarized below:

Hospital Centricity. Each bundle under the program is triggered by an inpatient stay, and in particular, by a specific Diagnostic Related Group, where there is significant variation in the total costs of episodes. This makes it more difficult to distinguish between warranted and unwarranted variation. Additionally, when regulators force every episode to be triggered by a hospital stay, they prevent physicians from exercising judgement in finding the best site for a given episode.

Lack of severity adjustment. The program does not provide a risk adjustment for patients with more complications. For example, a physician performing a total knee replacement for a patient with a serious heart condition would be paid the same to perform the surgery on a patient without complications. This provides an incentive for providers to favor certain patients over others in an effort to avoid losses.

Encouraging hospitalizations for acute exacerbations. The program includes bundles for patients with an Acute Myocardial Infarction (AMI), providing an incentive to hospitalize a patient with a mild AMI that normally would not require an inpatient stay. This runs counter to the purpose of alternative payment models, which is to encourage better management of patient conditions and reduce the potential for acute events.

Weak ties to quality measures. While hospitals enrolled in the CJR pilot and EPM must report certain quality measures, there are instances in which there are not any thresholds required to receive reconciliation payments. In other words, some could be rewarded for reducing cost relative to the target price, even if quality of care deteriorated.

Moving goalposts. One of the core principles of an effective payment model is to provide clear performance targets. The CJR pilot and EPM adjust the target to reflect changes in national trends, but the new targets are not revealed until at least six months after the performance period. This means participants will not know the standard to which they are being held during any given performance period, potentially encouraging participants to overestimate the probability of losses.

In his public comment letter to CMS Administrator Seema Verma, Altarum President and CEO Lincoln Smith states that “Altarum is a strong advocate of payment bundles and alternative payment models in general, but the proposed mandated models is the wrong approach.” He goes on to encourage CMS to consider a physician-focused model proposed by the American College of Surgeons, which “adjusts for patient severity, ties patient outcomes to gains and losses, enables physicians to exercise judgement in providing the best treatment, and encourages collaboration across disciplines.”

 

Five Key Standard Terms And Conditions Of The Washington 1115 Medicaid Waiver

Five Key Standard Terms and Conditions of the Washington 1115 Medicaid Waiver

On January 9, 2017 the Washington Healthcare Authority (HCA) reached a pivotal milestone in their partnership with the Centers for Medicare and Medicaid (CMS) to transform the delivery and quality of care served to their Medicaid population. The two parties finalized the Standard Terms and Conditions (STCs) of the 1115 Medicaid waiver, making the waiver officially approved, which up until that point had only been agreed-in-principle at the federal level. The STCs are an essential document as they outline the fundamental rules and regulations that HCA, the regional Accountable Communities of Health (ACHs) and providers throughout the state will have to follow as they begin to implement the transformation elements outlined in the waiver.

Over the coming months, HCA will develop the remaining governing documents of the waiver known as the protocols (or attachments to the STCs) and work to gain approval of these from CMS. These documents are critical as they will further define items such as:

  • Project valuation and the funds flow formula that will allocate the maximum dollars each ACH can earn through demonstrated performance
  • The semi-annual reporting requirements needed to demonstrate performance
  • Expectations around the collection and reporting of clinical quality outcomes
  • A number of other key governing regulations.

While the STCs are not complete until all of the protocols are developed and approved, this Health Insights piece will focus on five key terms outlined in the STCs related to the DSRIP program and offer suggestions as to things ACHs and community providers should begin to consider as they prepare for the implementation requirements of waiver participation. This piece is not intended to prescribe waiver next steps or compare other waiver programs; COPE Health Solutions has developed other thought leadership pieces that explain these elements of the Washington waiver and those articles are linked at the bottom of this piece.

 

Theranos agrees not to operate labs for two years

http://www.sfgate.com/business/article/Theranos-agrees-not-to-operate-labs-for-two-years-11079274.php

The Theranos lab in Newark Calif., seen on April 12, 2015. The company announced a settlement Monday with the Centers for Medicare and Medicaid Services that resolves all legal and regulatory proceedings between the federal agency and the embattled Palo Alto blood diagnostics firm. Photo: CARLOS CHAVARRIA, NYT

Theranos has reached a settlement with the Centers for Medicare and Medicaid Services that resolves all legal and regulatory proceedings between the federal agency and the embattled Palo Alto blood diagnostics firm, the company announced Monday.

Theranos has agreed to pay a penalty of $30,000 and cannot operate a clinical laboratory for the next two years.

As part of the settlement, the federal agency, which regulates blood testing labs, has withdrawn its revocation of Theranos’ lab operating certification.

Theranos, founded in 2003 by CEO Elizabeth Holmes, had been a high-flying startup that promised to revolutionize blood testing before a Wall Street Journal investigation alleged that the company misled people about the accuracy of its blood testing technology.

It is unclear whether the settlement has any bearing on investigations into the company by the Department of Justice and U.S. Securities and Exchange Commission. The company faces lawsuits from investors and Walgreens, its ex-partner that had been using Theranos blood-testing technology in dozens of stores before terminating the relationship.

The Wrong Way to Lower Health-Insurance Premiums

https://www.bloomberg.com/view/articles/2017-03-17/the-wrong-way-to-lower-health-insurance-premiums

Image result for high deductible health plan

For proponents of the American Health Care Act, perhaps the most encouraging nugget in the Congressional Budget Office’s otherwise critical analysis is that insurance premiums could fall by 10 percent on average by 2026. Even this prediction is more mirage than reality, however, in part because of an obscure concept known as “actuarial value.”

As many opponents of the Republicans’ Obamacare replacement legislation have already noted, for many people, the decline in premiums would be smaller than the cutback in their subsidies, so they would still end up paying more. And in any case, the predicted fall in premiums partly reflects a troubling rise in the share of older Americans without insurance, a change that would shift the enrollment pool to younger, less expensive beneficiaries.

Another factor, however, has received less attention, though it is hidden in plain sight in the CBO analysis: The premium reduction would occur in no small part because the insurance products wouldn’t be as good. In other words, their actuarial value would fall.

An insurance policy’s actuarial value is the share of total health-care costs paid by the plan rather than the policy holder, through deductibles and copayments. A plan with an actuarial value of 80 percent will pick up, on average, 80 percent of the cost of care. Plans with higher actuarial values have higher premiums, not surprisingly, because they provide deeper insurance. And if a plan’s actuarial value is very low, it may not really qualify as insurance at all.

The Affordable Care Act sets minimum actuarial values for each of the four tiers of plans that can be sold on the exchanges; the lowest, for bronze plans, is about 60 percent. The new legislation would repeal these minimums.

 In its analysis of the Republican proposal, the CBO found that insurers would offer lower-value policies “because they could offer a plan priced closer to the amount of the premium tax credit so that a younger person would have low out-of-pocket costs for premiums and would be more likely to enroll.” Similarly, insurers would hesitate “to offer plans with high actuarial values out of a fear of attracting a greater proportion of less healthy enrollees to those plans.” Since plans would still be required to cover 10 categories of essential health benefits, and since out-of-pocket limits would remain in place, plans would not dip too far below 60 percent, in the CBO’s estimation. But more plans would drop toward that level.

To see how big a deal this is, it is instructive to study the table toward the end of the CBO’s analysis, which calculates premiums under current law and under the AHCA. A 40-year-old single person could see his or her premium fall 7 percent — to $6,050, from $6,500. That’s only slightly less than the average 10 percent premium decline. Yet the actuarial value of the person’s plan would decline to 65 percent, from 70 percent or 87 percent, depending on his or her income.

To get some sense of what these lower actuarial values mean in terms of higher deductibles, we can look to the most recent Centers for Medicare and Medicaid Services calculator. It suggests that a plan with a $1,500 deductible, an 80 percent coinsurance rate (the plan pays 80 percent of costs above the deductible and below the maximum out-of-pocket threshold), and a $7,200 maximum out-of-pocket limit would have an actuarial value of 73 percent. The same plan with a $5,000 deductible would have an actuarial value of 61 percent. In other words, a decline in actuarial value of about 12 percentage points (not far from the average decline in the CBO examples) would raise the policy’s deductible by $3,500.

It’s no wonder that the premium for such a plan would be lower — in the same way that it’s no wonder a 12-ounce can of soda costs less than a 35-ounce bottle. It’s no great accomplishment to lower premiums by increasing other consumer costs.

As the CBO concluded, under the Republicans’ system, “individuals’ cost-sharing payments, including deductibles, in the nongroup market would tend to be higher than those anticipated under current law.” Indeed, according to an analysis from the Center for American Progress, average total costs to consumers would be significantly higher.

If you think that competition can fix this, note another problem that the CBO points out: Under Obamacare, the actuarial value requirements allow for easy comparison shopping; plan A can be directly compared with plan B. Under the Republican system, it would be harder to shop for a policy based on price.

Health-care reform is indeed complicated. Esoteric concepts like actuarial value have big effects on every family’s bottom line.

 

Editor’s Corner: Why are we still letting pharma pay physicians?

http://www.fiercehealthcare.com/antifraud/editor-s-corner-why-are-we-still-letting-pharma-pay-physicians

Close-up of a doctor's white coat

Last month, W. Carl Reichel was acquitted of charges that he oversaw a kickback scheme designed to induce physicians to prescribe certain drugs manufactured by Warner Chilcott LLC.

The president and CEO of the pharmaceutical company was acquitted of those charges despite the fact that the company itself pleaded guilty to “knowingly and willfully” paying off physicians in the form of sham speaking fees and meals at high-end restaurants, and agreed to pay the government $125 million in civil and criminal fines.

He was acquitted even though prosecutors trotted out nearly a dozen witnesses who worked under Reichel to testify against him, some of whom admitted to participating in the scheme that used “medical education” events–including barbecues, picnics, parties and trips to a casino–to improve physician prescribing rates. The government also alleged that Reichel oversaw the whole thing by demanding sales reps engage in “business conversations” about “clinical experience,” which was code for a physician’s prescribing rate.

But most importantly, he was acquitted because his attorneys never denied that he oversaw any of these payments, or that he instructed sales staff to take physicians out “at least twice a week.” They merely argued that “relationship building” is “widely accepted conduct” in the medical community.

They aren’t lying–allowing pharmaceutical companies to pay physicians large sums of money is a widely accepted practice. The question we should be asking ourselves is, why?

 

12 superbugs that pose the greatest danger to human health

http://www.fiercehealthcare.com/population-health/who-releases-list-12-priority-pathogens-to-encourage-drug-development?utm_medium=nl&utm_source=internal&mrkid=959610&mkt_tok=eyJpIjoiWkRjeU1tTTFPVEUyTjJaaCIsInQiOiJBNGU4aWlDQkpcL3l6eURqQUMyR2w3aVFtNStxVzBraUpQcTVOamQ4SVNEVUNDeXFQQ1RDWG5qdmptMjI4VWpiVTdHUDltN0ZTMG5ObWlHOWl0cXRmVEpjQ0h2bFU1NXJKM2YzaHBrcnc2VlVJVkoyTHJrQjBndGI5b3BGWmdJV1oifQ%3D%3D

Bacteria

The World Health Organization has released a list of 12 antibiotic-resistant superbugs that pose the greatest danger to human health.

The purpose of the list of “priority pathogens,” according to WHO, is to promote continued research and development of drugs that can be used to treat patients with these resistant infections.

The agency has divided the list according to the urgent need for new antibiotics. The bacteria considered the most critical pose a particular threat to hospitalized patients who may require blood catheters or ventilators. These bacteria, which can cause severe and deadly infections, such as bloodstream infections and pneumonia, are also resistant to drugs designed as a last line of defense for patients.

“This list is a new tool to ensure R&D responds to urgent public health needs,” Marie-Paule Kieny, Ph.D., assistant director-general for health systems and innovation at the WHO, said in an announcement. “Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time.”

Three bacteria resistant to carbapenem, an antibiotic that often treats bacteria that are resistant to other drugs, are listed as critical. Six bacteria are ranked as high-priority and the final three are listed as medium-priority. Bacteria listed as high- or medium-priority are increasingly becoming resistant to different antibiotics and are producing hard-to-treat strains of common conditions, such as gonorrhea and salmonella.

One of the three critical bacteria, carbapenem-resistant Enterobacteriaceae, or CRE, resulted in the death of a Nevada woman last year, and estimates suggest the infection may be more widespread than previously thought.

Global health experts have increasingly warned that superbugs are poised to be a significant threat to patient health. In the next decades, drug-resistant infections could kill more people than cancer. Providers can do their part by focusing on antibiotic stewardship. National healthcare organizations, including the Centers for Medicare & Medicaid Services, have offered guidelines.

Here is the complete list compiled by WHO:

IBM Watson Health debuts cloud solutions for value-based care

http://www.healthcaredive.com/news/ibm-watson-health-debuts-cloud-solutions-for-value-based-care/436527/

Dive Brief:

  • IBM Watson Health unveiled a new series of value-based cloud solutions aimed at helping providers, health plans and employers better manage their healthcare costs and quality.
  • The solutions — debuted at HIMSS17 in Orlando, FL—will integrate patient-level data from electronic health records and other sources to enhance understanding of different patient populations, risk factors and red flags at the individual, group and population level.
  • Watson Health also announced an agreement with Atrius Health to develop a cloud-based service to improve the doctor-patient experience.

Dive Insight:

The shift to value-based care and reimbursement models is forcing hospitals, payers and employers to rethink the way they manage risk in patient populations and come up with new approaches to improve quality while reducing costs. However, CMS’ new Quality Payment Program lacks needed IT infrastructure for collecting the data allowed by MACRA, which implemented the program, a recent HHS report concluded. But IBM is not the only company hoping to provide helpful solutions for value-based care. Earlier this month, Epic said it will incorporate care management content into its electronic health records (EHRs) and Health Catalyst deployed a new software tool that can be used to identify and align quality measure selection.

The value-based solutions set combines capabilities of Watson Care Manager, Truven Health Analytics, Phytel and Explorys. Initial applications, to be rolled out later this year, will focus on provider performance, patient engagement, bundled payments forecasting and management and custom analytics. Under the agreement with Atrius Health, Watson Cognitive Insights will combined the various influences on an individual’s health, including behavioral determinants, to improve primary care physicians’ effectiveness and efficiency and the quality and safety of ambulatory care. Among other things, the IBM solution could summarize key cognitive insights about a patient’s health status, assemble a de-identified cohort of similar patients and predict how those people might respond to various treatment options, according to the company.

During her keynote address at HIMSS17, IBM CEO Ginni Rometty talked of a new “golden age” in healthcare, thanks to cognitive computing, digitalhealth reports. Yet the industry must work to ease concerns about transparency, privacy of personal health information and artificial intelligence replacing highly skilled healthcare workers, she said. Rometty urged companies to invest in scalable — rather than piecemeal — solutions and to support an open platform, noting that will allow users to combine data being generated with their own insights.

Hospitals target nutrition, other social needs to boost health

http://www.usatoday.com/story/news/politics/2017/02/17/hospitals-target-nutrition-other-social-needs-boost-health/98042112/

Physician Joshua Sharfstein, former Maryland Secretary

Tom Shicowich “really, really, really liked Coca-Cola” before he began a new nutrition program targeting his Type 2 diabetes and weight. Being on a “very tight budget,” he couldn’t afford the fruit and vegetables he cut up for a living at his part-time grocery store job. Dinner was often a pizza or fast food meal he picked up on the way home.

Six months after getting free healthy groceries every week through the Geisinger hospital near his rural Pennsylvania home, Shicowich has cut his blood sugar level from nearly 11 to close to a normal level of 7. The 6′ 5″ former high school track team competitor has lost 35 pounds but is still nearly 200 pounds from his target weight of 250 pounds.

The Geisinger Health System is on its way to making its own numbers. On March 1, Geisinger plans to expand its five-patient pilot project to 50 more of its sickest and highest-cost diabetes patients. So far, all of those participating in Geisinger’s Fresh Food Pharmacy have lost weight, lowered their body mass indices, decreased their use of medication, lowered their cholesterol and improved their hemoglobin A1C levels, says Andrea Feinberg, an internal medicine doctor who is “clinical program champion.”

Geisinger is what’s known as an accountable care organization, which makes it fully responsible for the insurance and all health costs for their patients. They employ the doctors and own the hospitals and insurance company. The better-known Kaiser Permanente is another example. That means unlike other hospitals, their profits aren’t based upon patients’ visits and treatments.

“It is no coincidence that the health systems and hospitals that are doing it the best have aligned their incentives more closely to the health of their patients,” says Joshua Sharfstein, a pediatrician who is a former secretary of health for Maryland and top Food and Drug Administration official. “It’s very hard to ask a hospital that’s getting paid for every preventable admission to invest in ways that would eliminate those admissions.”

Read more:

What will become of MACRA, Obamacare, health IT? HIMSS boss weighs in (podcast)

What will become of MACRA, Obamacare, health IT? HIMSS boss weighs in (podcast)

HIMSS Chicago 2015

The annual Healthcare Information and Management Systems Society (HIMSS) conference gets under way Monday in Orlando, Florida, with numerous preconference activities starting Sunday.

As more than 40,000 people descend on Central Florida for the grueling event, MedCity News talked to HIMSS CEO and President H. Stephen Lieber for what has become an annual ritual, at least for this reporter. As usual, it’s on tape.

HIMSS17 is the last HIMSS conference with Lieber in charge; he announced in December that he would retire at the end of 2017.

Lieber is preparing to depart at a time when health IT is at a crossroads.

Healthcare organizations in the U.S. have spent the better part of the last 10 years installing and now optimizing electronic health records, though they continue to lag when it comes to sharing data across systems. And they continue to gripe about EHR usability and Meaningful Use requirements.

Providers in recent years also have grappled with updates to HIPAA regulations and the conversion to ICD-10 coding. Now, they face some new regulations affecting health IT.

Notably, the 2016 Medicare Access and CHIP Reauthorization Act (MACRA) is coming into force for ambulatory care. The rise of accountable care is “certainly having an impact already in terms of how care is not only delivered,” as well as how payers calculate reimbursements, Lieber noted.

They also face the uncertainty that comes with a change in administration in Washington.

Still, some things do remain relatively constant in health IT.

“The ongoing challenge in dealing with security, there is going to be an even greater focus this year as we try to bring more attention, more focus on what it takes to make sure that we’re handling data in a secure way,” Lieber said.

Clinical analytics has become a normal course of business in the field as well, though it has changed from merely clinical decision support and retrospective analytics to predictive analytics and machine learning. “As the field evolves, we’re evolving the programming with it.” Lieber noted.

Policy seems to be where a lot of intrigue is right now. It’s easy to make assumptions about what the new Trump administration might do, but assumptions are just that.